Allakos Announces Pricing of Initial Public Offering
19 juil. 2018 07h00 HE
|
Allakos Inc.
SAN CARLOS, Calif., July 19, 2018 (GLOBE NEWSWIRE) -- Allakos Inc., (Nasdaq:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various...
Allakos Highlights Data Demonstrating Potential of AK002 to Rapidly Deplete Eosinophils at 2018 AAAAI/WAO Joint Congress
05 mars 2018 09h45 HE
|
Allakos
-- Phase 1 data demonstrate AK002 rapidly depletes blood eosinophils after a single dose -- -- AK002 may provide an important new option in treating chronic allergic and inflammatory diseases such as...
Allakos Secures $100 Million In Series B Financing
13 déc. 2017 09h00 HE
|
Allakos
Proceeds will support advancement of AK002 in five disease areas Lead clinical program evaluating AK002 in eosinophilic gastroenteritis, an inflammatory gastrointestinal disease SAN CARLOS,...
Allakos Announces Additions to Senior Leadership Team
15 août 2017 10h01 HE
|
Allakos
Board of Directors appoints Robert Alexander as CEO and Adam Tomasi as COO & CFO Allakos plans to initiate a broad, multi-indication clinical program with AK002 in 2017 SAN CARLOS, Calif., Aug. ...